Global hepatitis report 2024: action for access in low- and middle-income countries

Action for access in low- and middle-income countries Global hepatitisreport 2024 Action for access in low- and middle-income countries Global hepatitis report 2024: action for access in low- and middle-income countries ISBN 978-92-4-009167-2 (electronic version)ISBN 978-92-4-009168-9 (print version) © World Health Organization 2024 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes,provided the work is appropriately cited, as indicated below. In any use of this work, there should be nosuggestion that WHO endorses any specific organization, products or services. The use of the WHO logo isnot permitted. If you adapt the work, then you must license your work under the same or equivalent CreativeCommons licence. If you create a translation of this work, you should add the following disclaimer along withthe suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is notresponsible for the content or accuracy of this translation. The original English edition shall be the binding andauthentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediationrules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation.Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva:World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.CIP data are available at https://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, see https://www.who.int/publications/book-orders.To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such astables, figures or images, it is your responsibility to determine whether permission is needed for that reuse andto obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers.The designations employed and the presentation of the material in this publication do notimply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country,territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dottedand dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsedor recommended by WHO in preference to others of a similar nature that are not mentioned. Errors andomissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication.However, the published material is being distributed without warranty of any kind, either expressed or implied.The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO beliable for damages arising from its use. Contents 3. Global status of access to health products 3.1Normative guidance3.2Access to diagnostics3.3Access to medicines3.4Access to vaccination 4. Regional landscape of access to health products 4.1African Region4.2Region of the Americas4.3South-East Asia Region4.4European Region4.5Eastern Mediterranean Region4.6Western Pacific Region 5. Looking ahead: public health action to eliminate viral hepatitis inlow- and middle-income countries by 2030 References Annex. Low- and middle-income countries and territories not included inat least one voluntary licensing agreement for viral hepatitis medicines, 2023220 Web Annex. Method for global reporting on disease burden and service coveragedata for viral hepatitis B and C Foreword advantage of price reductions, decentralize and integrateservice delivery and develop investment cases – keepingthe needs of people living with viral hepatitis at the centreof all efforts. In 2023, I had the honour of presenting Egypt with anofficial certification for becoming the first country toachieve gold tier status on the path to elimination forhepatitis C. This tremendous achievement could be withinthe reach of many other countries. We have the knowledgeand tools to prevent, diagnose and treat viral hepatitis,and the ability to deliver services at the primary healthcare level - closer to communities in need. Yet despitethis progress, most people around the world with chronichepatitis B and C are still wait